Equities analysts expect that PRA Health Sciences Inc (NASDAQ:PRAH) will report earnings of $1.29 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for PRA Health Sciences’ earnings, with estimates ranging from $1.26 to $1.30. PRA Health Sciences reported earnings per share of $1.13 during the same quarter last year, which indicates a positive year-over-year growth rate of 14.2%. The business is scheduled to announce its next earnings results on Wednesday, October 30th.

According to Zacks, analysts expect that PRA Health Sciences will report full year earnings of $5.05 per share for the current year, with EPS estimates ranging from $5.00 to $5.10. For the next fiscal year, analysts forecast that the company will report earnings of $5.74 per share, with EPS estimates ranging from $5.68 to $5.80. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Wednesday, July 31st. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.11. The firm had revenue of $763.31 million during the quarter, compared to analyst estimates of $764.95 million. PRA Health Sciences had a return on equity of 26.64% and a net margin of 5.39%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.00 earnings per share.

PRAH has been the topic of several recent analyst reports. Svb Leerink reissued a “market perform” rating on shares of PRA Health Sciences in a report on Tuesday, July 2nd. Jefferies Financial Group raised their price target on PRA Health Sciences from $115.00 to $120.00 and gave the company a “buy” rating in a report on Friday, September 6th. Leerink Swann initiated coverage on PRA Health Sciences in a research report on Tuesday, July 2nd. They issued a “market perform” rating and a $105.00 price objective for the company. BidaskClub raised PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Finally, Barclays increased their target price on PRA Health Sciences from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $115.00.

In related news, major shareholder Fund Holdings L.P. Kkr sold 6,666,684 shares of PRA Health Sciences stock in a transaction on Friday, September 6th. The stock was sold at an average price of $97.41, for a total transaction of $649,401,688.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.95% of the company’s stock.

Several hedge funds have recently made changes to their positions in PRAH. Vanguard Group Inc. grew its holdings in PRA Health Sciences by 1.3% during the second quarter. Vanguard Group Inc. now owns 6,371,495 shares of the medical research company’s stock valued at $631,734,000 after purchasing an additional 78,746 shares during the period. BlackRock Inc. raised its holdings in PRA Health Sciences by 0.9% in the first quarter. BlackRock Inc. now owns 6,211,391 shares of the medical research company’s stock worth $685,054,000 after purchasing an additional 52,524 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of PRA Health Sciences by 542.2% during the second quarter. Price T Rowe Associates Inc. MD now owns 4,699,572 shares of the medical research company’s stock worth $465,963,000 after purchasing an additional 3,967,806 shares in the last quarter. FMR LLC boosted its position in shares of PRA Health Sciences by 11.3% during the first quarter. FMR LLC now owns 2,881,740 shares of the medical research company’s stock worth $317,827,000 after purchasing an additional 292,887 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of PRA Health Sciences by 11.2% in the 2nd quarter. AQR Capital Management LLC now owns 2,028,713 shares of the medical research company’s stock valued at $194,655,000 after buying an additional 203,570 shares during the period. 99.64% of the stock is owned by institutional investors.

Shares of NASDAQ:PRAH traded up $1.47 on Friday, hitting $101.91. The stock had a trading volume of 546,959 shares, compared to its average volume of 565,366. The firm’s 50 day moving average price is $98.41 and its 200-day moving average price is $98.66. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.99 and a current ratio of 0.99. PRA Health Sciences has a twelve month low of $82.12 and a twelve month high of $121.98. The company has a market capitalization of $6.59 billion, a price-to-earnings ratio of 25.93, a price-to-earnings-growth ratio of 1.35 and a beta of 1.13.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Quiet Period

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.